during the post-generic period showed a pattern in which AE rates for the branded products were greater than for the generic products. Differences in rates of brand-and generic-attributed AEs were statistically significant for both study drugs; the AE rate for the branded products peaked at approximately 10 times that of the generic levetiracetam products and approximately 4 times that of the generic enoxaparin sodium products. In contrast, monthly ratios for the MarketScan data were relatively constant over time.
Conclusion: Use of the same nonproprietary name for generic and branded products may contribute to poor traceability of AEs reported in the FAERS database due to the significant misattribution of AEs to branded products (when those AEs were in fact associated with patient use of generic products). To ensure accurate and robust safety surveillance and traceability for biosimilar products in the United States, improved product identification mechanisms, such as related but distinguishable
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INTRODUCTION
Biologic therapies are medicinal products made by or derived from the living cells of humans, animals, or microorganisms [1] . Examples of biologic therapies include vaccines, blood products, cytokines, and monoclonal antibodies. Biosimilars, or follow-on biologics, are biologic therapies that are approved for marketing on the basis of data demonstrating that they have physicochemical and functional characteristics comparable to those of a previously licensed biologic therapy (i.e., the reference biologic). The manufacturing process for biologics, including biosimilars, is complex and prevents biosimilars from being exact replicas of the reference biologic. Differences in manufacturing processes could lead to small differences in a biosimilar's overall efficacy and safety profile, including immunogenicity [2] [3] [4] , which may not be detected in the abbreviated clinical and non-clinical premarket studies required for regulatory approval of the biosimilar product [3, 5] . Differences between a biosimilar and its reference product may also emerge over time due to manufacturing changes [6] . Further, biosimilars that share the same reference product need not meet regulatory standards of similarity with respect to each other, and thus may have different clinical profiles [7] . For these reasons, precise post-market traceability of biosimilars and reference biologics to further develop the adverse event (AE) profiles of, and identify any unexpected safety signals associated with, each biosimilar product is a point of key interest to health care providers, drug manufacturers, regulators, and policymakers. Whether biosimilars will or should be considered interchangeable with their reference biologics is a subject of debate [8] [9] [10] . The pathway to approval of a biosimilar therapy in the United States (US) is dictated by the Biologics Price Competition and Innovation Act of 2009 [7] . This legislation established a standard for demonstrating that a proposed product is ''biosimilar to'' the reference biologic as well as a separate standard for demonstrating that a biosimilar is ''interchangeable'' with the reference biologic [7] . 
METHODS

Study Drugs
We selected the antiepileptic drug levetiracetam 
AEs in the FAERS and MarketScan Data
Adverse events for each drug were identified 1 year before generic entry into the market and for up to 2 years after generic entry (Fig. 1 ).
With the date of final FDA regulatory approval as a proxy for entry into the market, 38 generic products for levetiracetam and 3 generic products for enoxaparin sodium were on the US market during the study period (i.e., the first 2 years after first generic entry) (see Table S1 , online-only supplemental information). Quarterly FAERS data were downloaded from the FAERS website for the period between 2007 Q1 and 2012 Q3; events from the US were identified and potential duplicate reports were removed as per FAERS guidelines [23] . The FAERS drug name variable was used to identify reports associated with the study drugs. All drug name values for reports remaining in this stage of the sample selection were reviewed, and reports corresponding to the study drugs (both the branded and generic names) were identified.
Only those reports where one of these drugs was identified as the primary suspect were included.
Potential misspellings of study drug names were Fig. 1 Generic entry dates and study periods for levetiracetam and enoxaparin sodium reviewed independently by two individuals to minimize exclusion of AE reports in which a study drug name was probably misspelled.
In the FAERS database, AEs are coded using is no parametric trend in the data [25] . A robust version of the algorithm resistant to the effects of outliers was used. 95% confidence intervals were constructed for the estimated trend from the standard error estimates of the residuals from the LOESS fit. Statistical analysis was carried out using R (version 3.0.0, R Foundation for Statistical Computing, Vienna, Austria).
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RESULTS
An overview of the number of AE reports and prescriptions for levetiracetam and enoxaparin sodium in both data sources is provided in Table 1 .
AE Rates for Levetiracetam
For the branded levetiracetam product in the FAERS dataset, the monthly trend in the AE rate was fairly constant during the period before generic entry and steadily increased over the two-year post-generic entry period (Fig. 2a) . For the generic levetiracetam products in the FAERS dataset, the monthly AE rate steadily decreased over time and stabilized approximately 1 year after entry (Fig. 2a) . In contrast to the FAERS data, the monthly AE rates for the branded levetiracetam product in the MarketScan claims data were fairly constant for the entire 3-year study period, and the AE rates of the branded and generic levetiracetam products were relatively constant during the 2-year postgeneric entry period (Fig. 2b) . Figure 3 compares the ratio of the monthly brand AE rate to the monthly generic AE rate for levetiracetam during the post-generic period FAERS Food and Drug Administration AE Reporting System, NPA National Prescription Audit for the two datasets. Although the ratios were nearly constant in the claims dataset, the ratio increased over time in the FAERS dataset; that is, the monthly AE rate for the branded levetiracetam product, was on average almost 10 times that of the generic products toward the end of the study period. This difference in the brand-to-generic AE rate ratios between the FAERS and claims data was statistically significant. 
AE Rates for Enoxaparin Sodium
For enoxaparin sodium, the trends were similar to those observed for levetiracetam but less pronounced (in Figs. 4a, b, 5 ). In the FAERS data, the monthly AE rates for the branded product increased over time after generic entry, whereas the monthly AE rates for the generic products decreased and then stabilized over time (Fig. 4a) . In the MarketScan data, the monthly AE rates were nearly constant for the branded enoxaparin sodium product over the three-year study period, and the monthly AE rates of the generic enoxaparin sodium products were relatively constant during the post-generic period (Fig. 4b) . The monthly AE rates ratios for the FAERS data indicate that the ratio increased and then stabilized to around 4 (i.e., the AE rate for the branded enoxaparin sodium product was 4 times that of the generic products on average) (Fig. 5) . In contrast, the monthly ratios for the claims data were almost constant over time. These differences were statistically significant.
DISCUSSION
When comparing FAERS-derived branded-and generic-attributed AEs against an insurance claims data source that has more strict requirements for product identification, one would expect that the branded and generic AE rates would be similar in both databases, given that these products share the same active drug substance and FDA has deemed them therapeutically equivalent. Consistent with this expectation, branded AE rates in a nationally representative claims database were nearly equal to those of the generic products and remained constant after generic introduction. The observed increase in branded-to-generic AE ratio in the FAERS data, in contrast, indicates that AEs in the FAERS
Fig. 3 FAERS and MarketScan
Ò adverse event rate ratios and 95% confidence intervals for levetiracetam during the postgeneric entry period. FAERS Food and Drug Administration Adverse Event Reporting System database were frequently misattributed to the branded product when a generic product was in fact associated with the AEs. Our study, thus, helps to confirm the findings of Lietzan et al. [14] , namely that AEs associated with generic products are often misattributed to branded products in FAERS data. These results suggest that FAERS data may not provide reliable traceability for generic drugs and their branded reference products, which share the Fig. 4 Enoxaparin sodium: monthly brand-and genericattributed adverse event rate and 95% confidence intervals during the pre-and post-generic entry periods. AE rates were calculated as the total monthly count of branded-or generic-attributed AEs divided by the total number of branded or generic prescriptions filled that month.
The dotted vertical line represents introduction of generic enoxaparin sodium; data points to the left of the line represent the pre-generic period and data points to the right of the line represent the postgeneric period. FAERS Food and Drug Administration Adverse Event Reporting System same nonproprietary name [14] . Moreover, a recent publication also evaluated potential misattribution AEs for enoxaparin generics in passive (i.e., FAERS) and active (i.e., claims data) surveillance [26] . The authors found that the number of AE reports processed by generic manufactures was much lower than expected based on market share and the number of events attributable to specific generic enoxaparin products was approximately ninefold lower than expected [26] .
The nomenclature for biosimilars has been debated in the US and internationally; however, no formal policy has been announced by the FDA as of January, 2015. Assuming that biosimilars would be susceptible to FAERS traceability issues similar to those found in our study (i.e., misattribution of AEs where products share the same nonproprietary name), our results can provide guidance to policy makers responsible for determining optimal nomenclature for biosimilars. Our study suggests that use of distinguishable nonproprietary names for biosimilars and reference biologics has the potential to enhance drug traceability and pharmacovigilance. Enhanced traceability in FAERS data would be useful, because despite that claims databases have strict product identification requirements that facilitate accurate AE attribution, they are not ideal for detection of unexpected AEs. Our study suggests that distinguishable nonproprietary names for biosimilars may be one way to help promote the attribution of AEs to the correct product [13, 27] , assisting the identification and tracking of safety information under the current system in the US.
In a prior study that investigated the traceability of products, including biosimilars, in the EU's EudraVigilance database, Vermeer et al. [4] reported that the specific biologic was identifiable in 96% of AE reports involving suspected biologics for which a biosimilar was In the AbbVie-sponsored study by Lietzan et al. [14] , which compared total brandattributed AEs in FAERS against total branded prescriptions filled, the number of brandattributed AEs tended to remain the same or increase as the total number of branded scripts decreased for 6 of the 8 branded/generic comparisons studied. The single NTI drug studied failed to show a pattern of misattribution of AEs to the branded product after introduction of the generic product, and 1 drug did not have sufficient data post-generic entry to determine whether a reliable trend existed. For the remaining 6 products, the increase in the ratio of brand-attributed AEs to branded prescriptions suggested that many of the AEs experienced by patients receiving the generic products likely were incorrectly reported as associated with the branded drug [14] . The present study confirmed this pattern of misattribution in the FAERS database for the LMWH drug enoxaparin sodium and also the NTI antiepileptic drug levetiracetam. Further, the present study expanded on the findings of Lietzan et al. [14] by demonstrating that the pattern of misattribution observed in the FAERS database did not occur in the nationally representative MarketScan claims database, a finding that was also reported in the Grampp et al. [26] study of enoxaparin generics.
In contrast, a policy paper issued by the chief scientific officer of Hospira [28] Likewise, it is possible that reporters may be more vigilant with regard to AE attribution for biosimilars, and misattribution rates could be lower with respect to biosimilars than observed in our study.
Another potential limitation is that some of the AE reports actually attributable to branded products in the FAERS database in the present study could have been identified only by generic name. Such cases would lead to a lower branded AE rate relative to the generic AE rate. Evidence from Lietzan et al. [14] , Grampp et al. [26] , and the present study, however, suggests that AE misattribution is likely to be more common in the other direction; that is, AEs associated with generic drugs are more likely to be reported by brand name.
The temporal reporting of prescriptions filled and the occurrence of an AE is the only way to directly link an AE to a specific drug in claims data. Thus, it is possible that some of the AEs attributed to the respective drugs in the MarketScan database may have been unrelated to the study drugs. The impact of this occurrence is probably minimal, for there is no reason to suspect bias in favor of branded vs. generic drugs.
Our study examined only data in the 1 year pre-and 2 years post-generic entry; it is possible that longer term data could have yielded more robust findings. Finally, our study used an assumption that the unknown number of prescriptions contributing to AEs in FAERS was proportional to the branded and generic drug market share in IMS. This assumption was based on the fact that IMS is a national representative sampling of prescription drug sales and, thus, is the best source available for such a calculation.
CONCLUSION
Results of the present study may have implications for the traceability of biosimilars once they enter the US market. To ensure accurate and robust safety surveillance and traceability for biosimilar products in the US, improved product identification mechanisms, such as related but distinguishable nonproprietary names for biosimilars and reference biologics, should be considered.
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